Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
On September 10, 2025, NeuroSense Therapeutics Ltd. announced promising initial results from its Phase 2 RoAD clinical trial for PrimeC, a drug candidate for Alzheimer’s disease. The trial, conducted in collaboration with NeuroKaire, demonstrated that PrimeC enhances neuroplasticity and has a favorable safety profile in Alzheimer’s patient-derived neurons. These findings support the drug’s mechanistic rationale and guide its precision development, potentially impacting the treatment landscape for Alzheimer’s disease. The results will be presented at the CNS Summit 2025 in Boston.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company aims to address significant unmet medical needs by developing combined therapies targeting multiple pathways associated with these complex diseases.
Average Trading Volume: 358,808
Technical Sentiment Signal: Sell
Current Market Cap: $28.54M
For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.